Answering questions about Pfizer/BioNTech’s COVID-19 vaccine
Yesterday we shared the good news about Pfizer/BioNTech’s announcement that their COVID-19 vaccine, currently in phase III trials, seems to be 90% effective.
But before we all celebrate a potential end to the pandemic (well, in a few months, anyway,
once the vaccine has undergone additional tests), there are a few important things to know.
A clear, insightful article by Kaiser Health News’s Arthur Allen addresses a few questions about the vaccine and its potential impact. One very interesting (and somewhat worrying) point is that, unlike many other COVID-19 vaccines in development, Pfizer/BioNTech’s must remain frozen at an extremely low temperature until only a few days before use. The company has had to come up with strategies for transporting the vaccines, and even training employees on how to handle it.
Read on to gain more insights into Pfizer/BioNTech’s COVID-19 vaccine.
Contact Our Writer – Alysa Salzberg